Your Article Summary
ONGLYZA (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
Bristol Myers-Squibb Company, 06/26/09
Bristol-Myers Squibb Company and AstraZeneca announced that their marketing authorization application for ONGLYZA received a positive opinion from the Committee for Medicinal Products for Human Use for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09
Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09
Shire Reports Tolerability and Clinical Effects Results of DAYTRANA from Study in Adolescents with ADHD
Shire, 11/02/09
Article Search
Sponsor


See Latest Articles


